Headquartered in Laarderhoogtweg 25, Amsterdam Fiscal year ends December NASDAQ: ARGX argenx.com
argenx is an immunology-focused biopharmaceutical company that develops antibody-based therapies for patients with severe autoimmune diseases. Its commercial franchise is built around VYVGART (efgartigimod), the first approved antibody fragment targeting the neonatal Fc receptor (FcRn), which reduces circulating IgG autoantibodies. VYVGART is approved for generalized myasthenia gravis (gMG) globally, chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan. The company offers both intravenous (VYVGART) and subcutaneous (VYVGART Hytrulo) formulations. Beyond VYVGART, argenx is advancing a diversified immunology pipeline including empasiprubart (anti-C2) in Phase 3 for multifocal motor neuropathy and CIDP, FB102 (CD122) advancing to Phase 3 in celiac disease, adimanebart (anti-MuSK) targeting congenital myasthenic syndromes, and multiple early-stage programs (ARGX-121, ARGX-109, TSP-101, ARGX-118, ARGX-125). The company operates a global commercial infrastructure across the United States, Japan, Europe, and other international markets. argenx co-creates with academic researchers through its Immunology Innovation Program to identify novel biology and develop treatments for underserved autoimmune conditions. Updated
As many as five new launches are lined up for 2027, spanning pediatric gMG, ocular MG, necrotizing myopathy, the autoinjector and empasiprubart in MMN, on the back of VYVGART product net sales growing 54% year over year. Both lines topped consensus even with Forte Biosciences deal costs sitting inside SG&A.
General Motors shed 7.5% into the close, the worst showing across 387 priority names and nearly double the next-biggest decline. GoPro and Clover Health anchored the other end, each up more than 7.5%.
Defense and big pharma own the top of the board at the open, led by Northrop Grumman up 5.36%, with Eli Lilly, Bristol-Myers Squibb and Merck also higher. The pain is concentrated in crypto miners and optics names, where IREN leads the decline.
argenx is down 10.91% at the open, more than double any other decliner in a 382-stock universe. Palantir leads the gainers at 4.17%, with Big Oil names filling out the rest.
Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly…
Pre-Market Stock Futures: Futures are trading higher on Thursday as we grind closer to the Christmas holiday, which is just a week off now. The song remains the same for the AI/Datacenter…
argenx is an immunology-focused biopharmaceutical company that develops antibody-based therapies for patients with severe autoimmune diseases.
24/7 Wall St.'s 12-month price target for ARGX is $1,244.49, rated Buy. The Wall Street consensus target is $1,147.35. ARGX price prediction →
